Literature DB >> 3792918

Serum immunoreactive cationic trypsinogen: a useful indicator of severe exocrine dysfunction in the paediatric patient without cystic fibrosis.

D J Moore, G G Forstner, C Largman, G J Cleghorn, S S Wong, P R Durie.   

Abstract

We evaluated serum cationic trypsinogen as a marker of exocrine pancreatic function in children without cystic fibrosis. The ability of this test to determine steatorrhoea of pancreatic origin, and its relationship to a wide range of exocrine pancreatic function were assessed. Serum trypsinogen was measured in 32 children with steatorrhoea, 10 with pancreatic and 22 with non-pancreatic causes. In patients with pancreatic steatorrhoea, serum cationic trypsinogen was 4.9 +/- 4.9 micrograms/l (mean +/- SD), significantly below values in patients with non-pancreatic steatorrhoea (47.0 +/- 22.1 micrograms/l, p less than 0.001) and 50 control subjects (31.4 +/- 7.4 micrograms/l, p less than 0.001). Serum cationic trypsinogen values in patients with pancreatic steatorrhoea all fell below the lower limit of our control range and below all values for patients with non-pancreatic steatorrhoea. Serum cationic trypsinogen was also evaluated against pancreatic trypsin output in 47 patients (range 0.2-17.0 yr who underwent a hormonal pancreatic stimulation test. In 17 patients, serum cationic trypsinogen was low (less than -2SD or less than 16.6 micrograms/l), and associated with greatly impaired pancreatic trypsin output, ranging from 0-8% of mean normal trypsin output. Five of these 17 patients did not have steatorrhoea. In 30 patients with normal or raised serum cationic trypsinogen (greater than or equal to 16.6 micrograms/l), pancreatic trypsin output ranged from 15-183% of mean normal values. In conclusion, low serum cationic trypsinogen suggests severely impaired exocrine pancreatic function, with sensitivity extending above the steatorrhoeic threshold. In the presence of steatorrhoea, low serum cationic trypsinogen indicates a pancreatic aetiology. Normal serum cationic trypsinogen, however, does not exclude impaired pancreatic function, above the steatorrhoeic threshold.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3792918      PMCID: PMC1434070          DOI: 10.1136/gut.27.11.1362

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  THE SYNDROME OF PANCREATIC INSUFFICIENCY AND BONE MARROW DYSFUNCTION.

Authors:  H SHWACHMAN; L K DIAMOND; F A OSKI; K T KHAW
Journal:  J Pediatr       Date:  1964-11       Impact factor: 4.406

2.  Classification of nutritional status in early childhood.

Authors:  D S McLaren; W W Read
Journal:  Lancet       Date:  1972-07-22       Impact factor: 79.321

3.  Development of a dual label Schilling test for pancreatic exocrine function based on the differential absorption of cobalamin bound to intrinsic factor and R protein.

Authors:  W R Brugge; J S Goff; N C Allen; E R Podell; R H Allen
Journal:  Gastroenterology       Date:  1980-05       Impact factor: 22.682

4.  Titrimetric measurements of fecal trypsin and chymotrypsin in cystic fibrosis with pancreatic exocrine insufficiency.

Authors:  W P Dyck
Journal:  Am J Dig Dis       Date:  1967-03

5.  Exocrine pancreatic function in juvenile-onset diabetes mellitus.

Authors:  B M Frier; J H Saunders; K G Wormsley; I A Bouchier
Journal:  Gut       Date:  1976-09       Impact factor: 23.059

6.  Pancreatic elastase in human serum. Determination by radioimmunoassay.

Authors:  M C Geokas; J W Brodrick; J H Johnson; C Largman
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

7.  Exocrine pancreatic insufficiency in celiac sprue: a cause of treatment failure.

Authors:  P T Regan; E P DiMagno
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

8.  Determination of human pancreatic cationic trypsinogen in serum by radioimmunoassay.

Authors:  M C Geokas; C Largman; J W Brodrick; J H Johnson
Journal:  Am J Physiol       Date:  1979-01

9.  Diagnostic importance of changes in circulating concentrations of immunoreactive trypsin.

Authors:  E Elias; M Redshaw; T Wood
Journal:  Lancet       Date:  1977-07-09       Impact factor: 79.321

10.  Plasma immunoreactive pancreatic cationic trypsinogen in cystic fibrosis: a sensitive indicator of exocrine pancreatic dysfunction.

Authors:  P R Durie; C Largman; J W Brodrick; J H Johnson; K J Gaskin; G G Forstner; M C Geokas
Journal:  Pediatr Res       Date:  1981-10       Impact factor: 3.756

View more
  6 in total

1.  Segregation analysis in Shwachman-Diamond syndrome: evidence for recessive inheritance.

Authors:  H Ginzberg; J Shin; L Ellis; S Goobie; J Morrison; M Corey; P R Durie; J M Rommens
Journal:  Am J Hum Genet       Date:  2000-03-14       Impact factor: 11.025

Review 2.  Cystic fibrosis. 6. Gastrointestinal and nutritional aspects.

Authors:  H Kopelman
Journal:  Thorax       Date:  1991-04       Impact factor: 9.139

Review 3.  Pathophysiology of the exocrine pancreas in cystic fibrosis.

Authors:  P R Durie; G G Forstner
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

4.  Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.

Authors:  James J Ross; Clive H Wasserfall; Rhonda Bacher; Daniel J Perry; Kieran McGrail; Amanda L Posgai; Xiaoru Dong; Andrew Muir; Xia Li; Martha Campbell-Thompson; Todd M Brusko; Desmond A Schatz; Michael J Haller; Mark A Atkinson
Journal:  Diabetes       Date:  2021-01-13       Impact factor: 9.461

5.  Serum Trypsinogen Levels in Type 1 Diabetes.

Authors:  Xia Li; Martha Campbell-Thompson; Clive H Wasserfall; Kieran McGrail; Amanda Posgai; Andrew R Schultz; Todd M Brusko; Jonathan Shuster; Faming Liang; Andrew Muir; Desmond Schatz; Michael J Haller; Mark A Atkinson
Journal:  Diabetes Care       Date:  2017-01-23       Impact factor: 19.112

Review 6.  Congenital etiologies of exocrine pancreatic insufficiency.

Authors:  Isabelle Scheers; Silvia Berardis
Journal:  Front Pediatr       Date:  2022-07-22       Impact factor: 3.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.